WO2023173024A3 - Treatment of coronary artery disease by reducing activity of cross-reactive t cells - Google Patents

Treatment of coronary artery disease by reducing activity of cross-reactive t cells Download PDF

Info

Publication number
WO2023173024A3
WO2023173024A3 PCT/US2023/064051 US2023064051W WO2023173024A3 WO 2023173024 A3 WO2023173024 A3 WO 2023173024A3 US 2023064051 W US2023064051 W US 2023064051W WO 2023173024 A3 WO2023173024 A3 WO 2023173024A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cross
coronary artery
artery disease
reactive
Prior art date
Application number
PCT/US2023/064051
Other languages
French (fr)
Other versions
WO2023173024A2 (en
Inventor
Patricia NGUYEN
Charles K.F. Chan
Mark M. Davis
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO2023173024A2 publication Critical patent/WO2023173024A2/en
Publication of WO2023173024A3 publication Critical patent/WO2023173024A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Coronary artery disease is treated by reducing the activation of CD8+ T cells that cross-react with a marker of cardiovascular cells and virus epitopes.
PCT/US2023/064051 2022-03-10 2023-03-09 Treatment of coronary artery disease by reducing activity of cross-reactive t cells WO2023173024A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263318596P 2022-03-10 2022-03-10
US63/318,596 2022-03-10

Publications (2)

Publication Number Publication Date
WO2023173024A2 WO2023173024A2 (en) 2023-09-14
WO2023173024A3 true WO2023173024A3 (en) 2023-10-26

Family

ID=87936003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/064051 WO2023173024A2 (en) 2022-03-10 2023-03-09 Treatment of coronary artery disease by reducing activity of cross-reactive t cells

Country Status (1)

Country Link
WO (1) WO2023173024A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097365A2 (en) * 2019-11-15 2021-05-20 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
WO2021163398A1 (en) * 2020-02-14 2021-08-19 Epivax, Inc. T cell epitope clusters and related compositions useful in the prevention, diagnosis, and treatment of covid-19
WO2021243005A2 (en) * 2020-05-28 2021-12-02 The Board Of Trustees Of The Leland Stanford Junior University Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097365A2 (en) * 2019-11-15 2021-05-20 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
WO2021163398A1 (en) * 2020-02-14 2021-08-19 Epivax, Inc. T cell epitope clusters and related compositions useful in the prevention, diagnosis, and treatment of covid-19
WO2021243005A2 (en) * 2020-05-28 2021-12-02 The Board Of Trustees Of The Leland Stanford Junior University Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces

Also Published As

Publication number Publication date
WO2023173024A2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MX2021013974A (en) Tl1a patient selection methods, systems, and devices.
MX2022004051A (en) Novel skin care composition.
CL2021002669A1 (en) (application divisional 3443-2018) cancer treatments.
MX2021010173A (en) Compounds with ferroptosis inducing activity and methods of their use.
MX2021000847A (en) Methods of treating cancer with pi3k inhibitor, gdc-0077.
MX2022004056A (en) Novel skin care composition.
WO2023173024A3 (en) Treatment of coronary artery disease by reducing activity of cross-reactive t cells
IL257929B1 (en) Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
MX2022006073A (en) Methods of use of anti-trem2 antibodies.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
WO2020016543A3 (en) Treatment of diseases involving nad
MX2022004055A (en) Novel skin care composition.
AU2020327022A8 (en) Method of treating cancer
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
WO2021046634A8 (en) Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
MX2022002245A (en) Compounds and methods for treating oxalate-related diseases.
MX2022004050A (en) Novel skin care composition.
MX2022004048A (en) Novel skin care composition.
MX2022014004A (en) Treatments of prostate cancer with combinations of abiraterone acetate and niraparib.
BR112023013052A2 (en) Monoclonal antibody against human mac-1 and its uses
WO2022097142A3 (en) Methods of prognosing, determining treatment course and treating multiple myeloma
ZA202300222B (en) Anti-αlpha-4-βeta-7 antibodies
MX2022003010A (en) Treatment of rms by switching therapy.
BR112022001814A2 (en) Multifocal cancer treatment methods
WO2023240199A3 (en) Fitusiran for the treatment of hemophilia a and b

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767704

Country of ref document: EP

Kind code of ref document: A2